{"schema_version":"secwatch.filing_event.v1","accession":"0001293971-24-000046","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2024-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.494830+00:00","generated_at":"2026-05-31T01:59:58.262719+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"bluebird bio cuts workforce 25%, targets 20% opex reduction and cash flow break-even in H2 2025","bullets":["Restructuring reduces headcount by ~25% and cash operating expenses by ~20% when fully realized in Q3 2025.","One-time cash charges of ~$3.7M for severance; stock-based compensation of $0.3M-$0.5M; most recorded in Q3 2024.","Cash flow break-even target in H2 2025 requires ~40 drug product deliveries per quarter and additional capital.","Year-to-date 41 patient starts; expects ~40 patient starts in Q4 2024 across three approved gene therapies.","Restructuring substantially complete by Q1 2025; savings fully realized Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001293971-24-000046","json":"https://secwatch.observer/filing/0001293971-24-000046.json","markdown":"https://secwatch.observer/filing/0001293971-24-000046.md","text":"https://secwatch.observer/filing/0001293971-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/0001293971-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/blue-20240923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:59:58.262719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b33995324a3c5912a1c99f69e641e4e88a926774","claim":"bluebird bio, Inc. announced a restructuring with charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs (approximately 25% of its headcount).","evidence_excerpt":"The Company’s board of directors approved the Restructuring on September 23, 2024, following a comprehensive review of the Company’s operations. The Restructuring includes a reduction of the Company’s workforce by approximately 25% of its headcount. As a result of the Restructuring, the Company estimates that it will incur aggregate charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs to be paid out over multiple weeks through the end of the fiscal year ending December 31, 2024, as well as approximately $0.3 million - $0.5 million in stock-based compensation expense.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000129397124000046/0001293971-24-000046-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.7 million in cash expenditures for severance and employee termination-related costs"},{"label":"Headcount","value":"approximately 25% of its headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}